8NE:FRA
Lisata Therapeutics, Inc.
0,82 €
arrow_downward
-0,61%(-0,0050) 1D
13 қаз., 11:46:17 GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 8NE...
Open
0,82 €
High
0,82 €
Low
0,82 €
Mkt. cap
11,24 млн
Avg. vol.
0,00
Volume
0,00
52-wk high
4,34 €
52-wk low
0,74 €
No. of employees
21
Open
0,82 €
High
0,82 €
Low
0,82 €
Mkt. cap
11,24 млн
Avg. vol.
0,00
Volume
0,00
52-wk high
4,34 €
52-wk low
0,74 €
No. of employees
21
News stories
From web sources and news partners
MarketBeat
·
20 минут бұрын
Nasdaq (NASDAQ:NDAQ) Stock Price Target Raised at Deutsche Bank Aktiengesellschaft
Seeking Alpha
·
1 сағат бұрын
Mentions of inflation have ballooned for tech companies – SoFi (SP500:)
The Lufkin Daily News
·
54 минут бұрын
S&P 500 flat as chipmakers fall and bank earnings roll in
Bloomberg.com
·
4 сағат бұрын
S&P 500 Record Rally Meets Risk of Peaking Earnings Growth
Profile
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
About Lisata Therapeutics, Inc.
CEO-
Employees21
Founded1980
HeadquartersBasking Ridge, Нью-Джерси, Америка Құрама Штаттары
Sector-
Websitelisata.com